[go: up one dir, main page]

MX2018009662A - Metodo y composicion farmaceutica para tratamiento de neurodegeneracion. - Google Patents

Metodo y composicion farmaceutica para tratamiento de neurodegeneracion.

Info

Publication number
MX2018009662A
MX2018009662A MX2018009662A MX2018009662A MX2018009662A MX 2018009662 A MX2018009662 A MX 2018009662A MX 2018009662 A MX2018009662 A MX 2018009662A MX 2018009662 A MX2018009662 A MX 2018009662A MX 2018009662 A MX2018009662 A MX 2018009662A
Authority
MX
Mexico
Prior art keywords
neurodegeneration
treatment
pharmaceutical composition
desferrioxamine
disorders
Prior art date
Application number
MX2018009662A
Other languages
English (en)
Inventor
Vinokur Vladimir
Berenshtein Eduard
Chevion Mordechai
Original Assignee
Chevion Mordechai
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chevion Mordechai filed Critical Chevion Mordechai
Publication of MX2018009662A publication Critical patent/MX2018009662A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/547—Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/315—Zinc compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/242—Gold; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/244—Lanthanides; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona composiciones farmacéuticas que comprenden un complejo de metal-desferrioxamina B o una combinación de los mismos, para prevenir, inhibir, reducir o mejorar la neurodegeneración, tratando de esta manera enfermedades, trastornos, o afecciones caracterizadas por o asociadas con neurodegeneración; así como también métodos de uso.
MX2018009662A 2016-02-11 2017-02-08 Metodo y composicion farmaceutica para tratamiento de neurodegeneracion. MX2018009662A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662293803P 2016-02-11 2016-02-11
PCT/IL2017/050159 WO2017137988A1 (en) 2016-02-11 2017-02-08 Method and pharmaceutical composition for treatment of neurodegeneration

Publications (1)

Publication Number Publication Date
MX2018009662A true MX2018009662A (es) 2018-09-11

Family

ID=59563756

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018009662A MX2018009662A (es) 2016-02-11 2017-02-08 Metodo y composicion farmaceutica para tratamiento de neurodegeneracion.

Country Status (11)

Country Link
US (1) US11033630B2 (es)
EP (1) EP3413882A4 (es)
JP (1) JP7003045B2 (es)
KR (1) KR20180105701A (es)
CN (1) CN108601750A (es)
AU (1) AU2017216926A1 (es)
CA (1) CA3012582A1 (es)
IL (1) IL260890A (es)
MX (1) MX2018009662A (es)
SG (1) SG11201806157WA (es)
WO (1) WO2017137988A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020010829A (es) * 2018-04-13 2021-03-25 Mordechai Chevion Composiciones y metodos para el tratamiento de la desmielinización.
EP3781143A4 (en) * 2018-04-15 2022-01-05 Mordechai Chevion COMPOSITIONS AND METHODS FOR THE TREATMENT OF IRON OVERLOAD
US11779597B2 (en) * 2019-10-11 2023-10-10 Vector Vitale Ip Llc Method of treating Parkinson's and other neurodegenerative diseases
CN115919895A (zh) * 2019-12-27 2023-04-07 武汉广行科学研究有限公司 用于治疗多发性硬化症的组合物和方法
KR102499338B1 (ko) * 2021-02-03 2023-02-10 한림대학교 산학협력단 알츠하이머병의 예방 또는 치료용 약학 조성물
KR102674622B1 (ko) * 2021-10-15 2024-06-11 아주대학교산학협력단 데페록사민을 포함하는 근감소증의 예방, 개선 또는 치료용 조성물

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
MX12394A (es) * 1987-07-23 1993-12-01 Ciba Geigy Ag Procedimiento par la obtencion de carbamatos de polietilenglicol.
IL91047A (en) 1989-07-19 1993-06-10 Yissum Res Dev Co Zinc complexes for the treatment of free radical- induced diseases
US5618838A (en) * 1993-06-18 1997-04-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Gallium complexes for the treatment of free radical-induced diseases
GB0108770D0 (en) * 2001-04-06 2001-05-30 Eisai London Res Lab Ltd Inhibitors
WO2004060490A1 (en) * 2003-01-07 2004-07-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Composition comprising a desferrioxamine-metal complex and its use for treating tissue damage following exposure to warfare agent
US7618615B2 (en) * 2004-08-13 2009-11-17 Healthpartners Research Foundation Methods for providing neuroprotection for the animal central nervous system against neurodegeneration caused by ischemia
US9216161B2 (en) * 2004-08-13 2015-12-22 Healthpartners Research Foundation Methods of treating Huntington's disease comprising administering metal chelators to the upper one-third of the nasal cavity
BRPI0615349A2 (pt) * 2005-09-02 2011-05-17 Neuraxo Biopharmaceuticals Gmbh composição farmacêutica compreendendo um quelador de ferro
US8975294B2 (en) 2009-08-19 2015-03-10 Hadasit Medical Research Services And Development Ltd. Desferrioxamine-metal complexes for the treatment of immune-related disorders

Also Published As

Publication number Publication date
EP3413882A1 (en) 2018-12-19
IL260890A (en) 2018-10-31
US11033630B2 (en) 2021-06-15
JP2019519465A (ja) 2019-07-11
CN108601750A (zh) 2018-09-28
KR20180105701A (ko) 2018-09-28
CA3012582A1 (en) 2017-08-17
WO2017137988A1 (en) 2017-08-17
SG11201806157WA (en) 2018-08-30
US20190358334A1 (en) 2019-11-28
AU2017216926A1 (en) 2018-08-02
JP7003045B2 (ja) 2022-02-04
EP3413882A4 (en) 2019-10-09

Similar Documents

Publication Publication Date Title
ZA202405294B (en) Heterocyclic compounds as immunomodulators
PH12019500521A1 (en) Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
IL285782A (en) Compounds, compositions, and methods for treating disease
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
MX2022005290A (es) Compuestos heterociclicos como inmunomoduladores.
MX2019003623A (es) Composiciones y metodos para el tratamiento de afecciones oftalmicas.
MX2017016424A (es) Compuestos para su uso en el tratamiento de trastornos neuromusculares.
PH12018501084A1 (en) Heterocyclic compounds as immunomodulators
MX2018003472A (es) Moduladores de la expresion de kras.
EP4327809A3 (en) Tyk2 inhibitors and uses thereof
MX2018006632A (es) Inhibidores biciclicos de peptidilarginina deiminasa 4 (pad4).
MX2017004618A (es) Inhibidores de la biosintesis de sulfato de heparano para el tratamiento de enfermedades.
MX2018009662A (es) Metodo y composicion farmaceutica para tratamiento de neurodegeneracion.
MX2018006700A (es) Inhibidores aza-bencimidazol de peptidilarginina desiminasa (pad4).
WO2015200790A3 (en) Compositions and methods to regulate renalase in the treatment of diseases and disorders
PH12016500140A1 (en) Heterobicycloaryl rorc2 inhibitors and methods of use thereof
EP4289820A3 (en) Compounds for use in treating alzheimer's disease in apoe4+/+ patients
MX2017004808A (es) Combinaciones que comprenden siponimod y laquinimod para el tratamiento de la esclerosis multiple.
ZA202000375B (en) Compounds for the prevention and treatment of medical disorders and uses thereof
EP3681477A4 (en) PROCEDURES AND IMPROVED COMPOSITION FOR TREATMENT OF TREITERPEN RESPONSIBLE CONDITIONS, DISEASES, OR DISORDERS
PH12020550023A1 (en) Compositions for treating stress-related disorders
MX2019006863A (es) Inhibidores de heparanasa y uso de los mismos.
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
PH12019500198A1 (en) Compounds and compositions and uses thereof
MX2017004819A (es) Metodos de tratamiento de transtornos urológicos usando sarm.